Cytogen's ProstaScint enters IMRT (intensity modulated radiation therapy) trials:
This article was originally published in Clinica
A phase I/II clinical study is underway to evaluate Cytogen's ProstaScint imaging agent in improving the precision of intensity modulated radiation therapy (IMRT) for prostate cancer. ProstaScint, a radiolabelled monoclonal antibody, is injected intravenously into the patient where it binds to a highly expressed marker for prostate cancer. The enhanced images will allow for radiation to be more highly focused on the tumour, reducing damage to the surrounding tissue, said the Princeton, New Jersey firm.
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.